Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22661725 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL918791 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL29549533 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL1685684 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL30403231 | 0.98 | NPC1 (0.42) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL29001613 | 0.98 | NPC1 (0.42) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL19765232 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL27932371 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12116904 | 0.80 | NPC1 (0.38) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL20500207 | 0.79 | NPC1 (0.40) | NPC1MEN1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596898-B2 | Making a 2-fluoro-2-chlorocyclopropanecarboxylic acid derivative stereoselectively in high yield by reacting a diazoacetic acid derivative with 1-fluoro-1-chloroethylene using metal catalyst having chiral ligands | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | claimed |
| US-20240376257-A1 | POLY(GLYCOLIC ACID) FOR CONTAINERS AND FILMS WITH REDUCED GAS PERMEABILITY | DAK AMERICAS LLC (US) | 2024-11-14 | — | — | US | disclosed |
| WO-2022036040-A1 | SYNTHESIS OF SMALL MOLECULES INSPIRED BY PHOMOXANTHONE A | WORCESTER POLYTECHNIC INSTITUTE (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220048879-A1 | Synthesis of small molecules inspired by Phomoxanthone A | WORCESTER POLYTECHNIC INSTITUTE | 2022-02-17 | — | — | US | disclosed |
| US-11046649-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3823604-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE | Board of Regents, The University of Texas System (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020018670-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-01-23 | — | — | WO | disclosed |
| US-8969585-B2 | Method for producing optically active compound or salt thereof | NAGASAKI UNIVERSITY (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140012010-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF | NAGASAKI UNIVERSITY (JP) | 2014-01-09 | — | — | US | disclosed |
| US-8252919-B2 | 2′-hydroxy-protected ribonucleoside derivative and production method thereof | KANEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258709-A1 | 2'-HYDROXYL-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND MANUFACTURING METHOD OF SAME | Kaneka Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-6596898-B2 | Making a 2-fluoro-2-chlorocyclopropanecarboxylic acid derivative stereoselectively in high yield by reacting a diazoacetic acid derivative with 1-fluoro-1-chloroethylene using metal catalyst having chiral ligands | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20010051750-A1 | PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0858992-B1 | PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2001-12-12 | — | — | EP | disclosed |
| EP-0858992-A1 | PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | NPC1 1978/4885MEN1 3696/4885KMT2A 721/4885 |
| US-20140012010-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF | MINK1, MELK, MRPL21 | NPC1 3407/4885MEN1 812/4885KMT2A 1867/4885 |
| US-20010051750-A1 | PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES | CYP2F1, CYP4F2, CYP4F8 | NPC1 342/4885MEN1 2065/4885KMT2A 1552/4885 |
| US-11046649-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | IDO1, IDO2, TDO2 | NPC1 3065/4885MEN1 2563/4885KMT2A 743/4885 |
| US-20220048879-A1 | Synthesis of small molecules inspired by Phomoxanthone A | ERG28, SQLE, PHKA1 | NPC1 4064/4885MEN1 1048/4885KMT2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.